RDD 2026: Connect with the Intertek team

Join our team at the Respiratory Drug Delivery (RDD) 2026 Conference (May 10–14, Phoenix, Arizona) to discuss the latest challenges and innovations in pulmonary and nasal drug development.

Get in touch with our team now - We’ll be available throughout the event to explore your OINDP development programmes, including:

• Formulation optimisation for local and systemic delivery
• Nasal drug development and emerging delivery pathways
• Particle engineering and device–formulation alignment
• Clinical trial material manufacturing and CMC support
• Analytical services for OINDP development
• Advanced in vitro testing strategies (IV-BE, IV-IVC, realistic breathing profiles)
• Stability Programmes
• Extractables/leachables
  
  

Our experts will also be sharing updates on the commissioning of our new GMP facility in Melbourn, Cambridge (UK), adding 29,000 sq ft of manufacturing and analytical capacity. Designed to support next-generation inhaled and nasal therapies, including biologics for respiratory delivery, this expansion enables parallel clinical manufacturing campaigns with the flexibility to adapt to evolving programme needs.

Backed by integrated formulation, analytical, and manufacturing teams, we support development from early pre-formulation and solubility screening through to device selection, stability studies, and GMP clinical manufacturing. Our capabilities also include comprehensive protein characterisation, ensuring critical quality attributes such as structure, stability, and potency are maintained throughout development.

Get in touch to arrange a meeting in Phoenix and explore how we can support your programme from concept to clinic.

Latest respiratory drug delivery resources: 
Guide: Key Considerations for Developing Intranasal Nucleic Acid Therapies for CNS Targets
Our experts provide a concise overview of the key challenges and emerging opportunities in developing intranasal delivery strategies for mRNA and oligonucleotide therapeutics targeting the central nervous system.

Q&A: Building Flexibility into the Future of Next Generation Therapies: Expanded CTM Manufacturing and Integrated Analytical Resources
This expert interview with Teresa Iley, our Director Pharmaceutical Development & Manufacturing, explores how greater flexibility can be integrated into the development of inhaled and nasal drug products to address increasing complexity in formulation, device design, and regulatory expectations.

Missed our RDD Europe 2025 Conference Poster?
This study looked at both currently marketed subcutaneous injection formulations and prototype formulations to investigate the effect of higher drug loading. here: Aerosolization of Wegovy® and Prototype Formulations of Semaglutide with MRX004 SMI

BROCHURE | Intertek Inhaled Product Development Services 
BROCHURE | Inhaled Biologic Drug Development Services